BeyondSpring Inc BYSI shares are trading higher by 22.5% at $26.59 Friday afternoon on continued strength after the company earlier in the week announced results from its DUBLIN-3 trial of plinabulin in combination with docetaxel, which met its primary endpoint.
See Also: BeyondSpring CEO Talks Better-Than-Expected Trial Results That Sent The Stock Soaring
BeyondSpring is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies.
BeyondSpring is also focused on including immuno-oncology agents. The company has created Plinabulin which is a marine-derived small molecule with a number of distinct biological activities that may provide multiple therapeutic opportunities.
BeyondSpring has a 52-week high of $30.01 and a 52-week low of $8.90.
Edge Rankings
Price Trend
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
